ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO120

Renal Safety of FLOT Regimen for Gastroesophageal Cancer: Time for Break Boundaries?

Session Information

Category: Onconephrology

  • 1600 Onconephrology

Authors

  • Trevisani, Francesco, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Floris, Matteo, Azienda Ospedaliera Brotzu, Cagliari, Sardegna, Italy
  • Cinque, Alessandra, BIOREK s.r.l., Milan, Lombardia, Italy
  • Minnei, Roberto, Azienda Ospedaliera Brotzu, Cagliari, Sardegna, Italy
  • Pani, Antonello, Azienda Ospedaliera Brotzu, Cagliari, Sardegna, Italy
  • Angioi, Andrea, Azienda Ospedaliera Brotzu, Cagliari, Sardegna, Italy
  • Scartozzi, Mario, Universita degli Studi di Cagliari, Cagliari, Sardegna, Italy
  • Puzzoni, Marco, Universita degli Studi di Cagliari, Cagliari, Sardegna, Italy
  • Amodeo, Jaime, Universita degli Studi di Cagliari, Cagliari, Sardegna, Italy
  • Liscia, Nicole, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Mazza, Elena A., IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Cascinu, Stefano, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
Background

Currently, peri-operative docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) chemotherapy (CTx) is the gold standard treatment for pts with locally advanced gastric cancer (LAGC), who undergo peri-operative CTx and surgery. The nephrotoxicity of both docetaxel and oxaliplatin may limit the use in CKD pts. Since limited evidence is available, we explored FLOT effects on renal function in our LAGC population.

Methods

Retrospective data on patient with LAGC in 3 tertiary hospital between jan/2018 to jan/2022 have been analyzed. Pts have been treated with FLOT, administered every 2 weeks, 4 times before surgery. SCr, Hb, and CKD-EPI eGFR were detected before each cycle. AKI and CKD onset/prevalence were determined according to K-DIGO criteria.

Results

A consecutive cohort of 73 pts was enrolled. Baseline CKD was present in 16 pts (21.9%). Median eGFR was 106.2 ml/min. ANOVA showed no significant differences between cycles in eGFR decay and CKD onset; p=0.323 (Table 1 and Figure 1). AKI was very low (1 episode of stage2 (0,7%). New onset anemia was the only significant adverse event observed (p=0.003).

Conclusion

Surprisingly, the pre-operative FLOT regimen seems to have a negligible impact on renal function suggesting the possibility to extend its use even in patient with advanced CKD.

Funding

  • Private Foundation Support